In today’s session bluebird bio Inc (BLUE) registered an unusually high (724) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious BLUE increase. With 724 contracts traded and 1404 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: BLUE161021C00060000 closed last at: $1.3 or 81.2% down. About 232,410 shares traded hands. bluebird bio Inc (NASDAQ:BLUE) has risen 26.51% since March 15, 2016 and is uptrending. It has outperformed by 21.03% the S&P500.
Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on November, 2. They expect $-1.48 EPS, down 25.42% or $0.30 from last year’s $-1.18 per share. After $-1.59 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -6.92% EPS growth.
bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage
Out of 13 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 77% are positive. $244 is the highest target while $14 is the lowest. The $113 average target is 103.24% above today’s ($55.6) stock price. bluebird bio has been the topic of 28 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Leerink Swann initiated the stock with “Outperform” rating in Wednesday, February 3 report. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock has “Buy” rating given by Roth Capital on Saturday, August 15. The firm has “Buy” rating by TH Capital given on Thursday, December 3. The firm earned “Buy” rating on Wednesday, November 18 by Goldman Sachs. On Thursday, December 3 the stock rating was initiated by Roth Capital with “Buy”. The stock has “Outperform” rating given by Leerink Swann on Friday, October 14. As per Friday, October 14, the company rating was downgraded by Cantor Fitzgerald. The stock has “Buy” rating given by Roth Capital on Friday, August 28. The stock has “Hold” rating given by Cantor Fitzgerald on Friday, June 3.
According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.34, from 1.34 in 2016Q1. The ratio fall, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Da Davidson holds 0% or 900 shares in its portfolio. North Star Mgmt holds 0% or 150 shares in its portfolio. The United Kingdom-based Blackrock Gp has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Williams Jones And Limited Liability Company accumulated 0.01% or 5,850 shares. Parametric Portfolio Associates Ltd Llc reported 18,904 shares or 0% of all its holdings. Great Point Prns accumulated 500,000 shares or 6.2% of the stock. Tci Wealth Advsrs reported 111 shares or 0% of all its holdings. Svcs Automobile Association last reported 0.01% of its portfolio in the stock. Manufacturers Life Ins The, a Ontario – Canada-based fund reported 25,166 shares. Portolan Cap Limited Liability Company, a Massachusetts-based fund reported 37,090 shares. The Delaware-based Tiverton Asset Management Lc has invested 0.54% in bluebird bio Inc (NASDAQ:BLUE). Paradigm Asset Management Limited Liability holds 0% or 350 shares in its portfolio. Rech Global Invsts last reported 0.07% of its portfolio in the stock. Swiss Commercial Bank reported 59,707 shares or 0% of all its holdings. Vanguard Group Inc Inc has invested 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE).
bluebird bio, Inc. is a biotechnology company. The company has a market cap of $2.03 billion. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. It currently has negative earnings. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
BLUE Company Profile
bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More news for bluebird bio Inc (NASDAQ:BLUE) were recently published by: Fool.com, which released: “Why Shares of bluebird bio Inc Took a Dive Today” on October 14, 2016. Fool.com‘s article titled: “Why bluebird bio, Inc. Stock Soared 37.4% in September” and published on October 11, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.